High throughput screening technologies for ion channels

Acta Pharmacologica Sinica

Volumn 37, Issue 1, 2016, Pages 34-43

  Yu, Hai Bo ^a   Li, Min ^a   Wang, Wei Ping ^a   Wang, Xiao Liang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

automated electrophysiological assay; drug discovery; fluorescence based assay; flux based assay; high throughput screening; ion channels; ligand binding assay

Indexed keywords

CALCIUM CHANNEL; CALCIUM ION INVOLVED ION CHANNEL; CHLORIDE CHANNEL; FLUORESCENT DYE; ION CHANNEL; ION SPECIFIC FLUORESCENT PROBE; POTASSIUM CHANNEL; POTASSIUM SELECTIVE CHANNEL; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

AUTOMATED ELECTROPHYSIOLOGICAL ASSAY; ELECTROPHYSIOLOGICAL ASSAY; FLUORESCENCE ANALYSIS; FLUX ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; RECEPTOR BINDING ASSAY; REVIEW; VOLTAGE SENSITIVE DYE IMAGING; ANIMAL; DRUG DESIGN; METABOLISM; PROCEDURES;

ANIMALS; DRUG DESIGN; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ION CHANNELS;

EID: 84953304250     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2015.108     Document Type: Review

References (92)

1. Curran J, Mohler PJ. Alternative paradigms for ion channelopathies: disorders of ion channel membrane trafficking and posttranslational modification. Annu Revi Physiol 2015; 77: 505-24.
2. Kullmann DM, Waxman SG. Neurological channelopathies: new insights into disease mechanisms and ion channel function. J Physiol 2010; 588: 1823-7.
3. Felix R. Channelopathies: ion channel defects linked to heritable clinical disorders. J Med Genet 2000; 37: 729-40.
4. Ptacek LJ. Channelopathies: ion channel disorders of muscle as a paradigm for paroxysmal disorders of the nervous system. Dig Dis Sci 1999; 44: 94S-96S.
5. Bowes J, Brown A, Hamon J, Jarolimek W, Sridhar A, Waldron G, et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov 2012; 11: 909-22.
6. Gill S, Gill R, Lee SS, Hesketh JC, Fedida D, Rezazadeh S, et al. Flux assays in high throughput screening of ion channels in drug discovery. Assay Drug Dev Technol 2003; 1: 709-17.
7. Finlayson K, Pennington AJ, Kelly JS. [3H] dofetilide binding in SHSY5Y and HEK293 cells expressing a HERG-like K+ channel? Eur J Pharmacol 2001; 412: 203-12.
8. Diaz GJ, Daniell K, Leitza ST, Martin RL, Su Z, McDermott JS, et al. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. J Pharmacol Toxicol methods 2004; 50: 187-99.
9. Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, et al. Validation of a [3H] astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci 2004; 95: 311-9.
10. Huang XP, Mangano T, Hufeisen S, Setola V, Roth BL. Identification of human Ether-Á-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay Drug Dev Technol 2010; 8: 727-42.
11. Hamilton TC, Weir SW, Weston AH. Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br J Pharmacol 1986; 88: 103-11.
12. Weir SW, Weston AH. The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vessels. Br J Pharmacol 1986; 88: 121-8.
13. Terstappen GC. Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay. Anal Biochem 1999; 272: 149-55.
14. Liu K, Samuel M, Harrison RK, Paslay JW. Rb+ efflux assay for assessment of non-selective cation channel activities. Assay Drug Dev Technol 2010; 8: 380-8.
15. Chaudhary KW, O'Neal JM, Mo ZL, Fermini B, Gallavan RH, Bahinski A. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade. Assay Drug Dev Technol 2006; 4: 73-82.
16. Scott CW, Wilkins DE, Trivedi S, Crankshaw DJ. A mediumthroughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry. Anal Biochem 2003; 319: 251-7.
17. Terstappen GC. Nonradioactive rubidium ion efflux assay and its applications in drug discovery and development. Assay Drug Dev Technol 2004; 2: 553-9.
18. Epps DE, Knechtel TJ, Bacznskyj O, Decker D, Guido DM, Buxser SE, et al. Tirilazad mesylate protects stored erythrocytes against osmotic fragility. Chem Phys Lipids 1994; 74: 163-74.
19. Gonzalez JE, Tsien RY. Voltage sensing by fluorescence resonance energy transfer in single cells. Biophys J 1995; 69: 1272-80.
20. Whiteaker KL, Gopalakrishnan SM, Groebe D, Shieh CC, Warrior U, Burns DJ, et al. Validation of FLIPR membrane potential dye for high throughput screening of potassium channel modulators. J Biomol Screen 2001; 6: 305-12.
21. Kao JP, Harootunian AT, Tsien RY. Photochemically generated cytosolic calcium pulses and their detection by fluo-3. J Biol Chem 1989; 264: 8179-84.
22. Minta A, Kao JP, Tsien RY. Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. J Biol Chem 1989; 264: 8171-8.
23. Beacham DW, Blackmer T, M OG, Hanson GT. Cell-based potassium ion channel screening using the FluxOR assay. J Biomol Screen 2010; 15: 441-6.
24. Weaver CD, Harden D, Dworetzky SI, Robertson B, Knox RJ. A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. J Biomol Screen 2004; 9: 671-7.
25. Meuwis K, Boens N, De Schr yver FC, Gallay J, Vincent M. Photophysics of the fluorescent K+ indicator PBFI. Biophys J 1995; 68: 2469-73.
26. Minta A, Tsien RY. Fluorescent indicators for cytosolic sodium. Biol Chem 1989; 264: 19449-57.
27. Galietta LJ, Haggie PM, Verkman AS. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS lett 2001; 499: 220-4.
28. Wachter RM, Remington SJ. Sensitivity of the yellow variant of green fluorescent protein to halides and nitrate. Curr Biol 1999; 9: R628-9.
29. Jayaraman S, Haggie P, Wachter RM, Remington SJ, Verkman AS. Mechanism and cellular applications of a green fluorescent proteinbased halide sensor. J Biol Chem 2000; 275: 6047-50.
30. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50.
31. Song Y, Buelow B, Perraud AL, Scharenberg AM. Development and validation of a cell-based high-throughput screening assay for TRPM2 channel modulators. J Biomol Screen 2008; 13: 54-61.
32. Miller M, Shi J, Zhu Y, Kustov M, Tian JB, Stevens A , et al. Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J Biol Chem 2011; 286: 33436-46.
33. Dai G, Haedo RJ, Warren VA, Ratliff KS, Bugianesi RM, Rush A, et al. A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. Assay Drug Dev Technol 2008; 6: 195-212.
34. Finkel A, Wittel A, Yang N, Handran S, Hughes J, Costantin J. Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J Biomol Screen 2006; 11: 488-96.
35. Trivedi S, Dekermendjian K, Julien R, Huang J, Lund PE, Krupp J, et al. Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators. Assay Drug Dev Technol 2008; 6: 167-79.
36. Bridgland-Taylor MH, Hargreaves AC, Easter A, Orme A, Henthorn DC, Ding M, et al. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J Pharmacol Toxicol Methods 2006; 54: 189-99.
37. Wible BA, Kuryshev YA, Smith SS, Liu Z, Brown AM. An ion channel library for drug discovery and safety screening on automated platforms. Assay Drug Dev Technol 2008; 6: 765-80.
38. Gillie DJ, Novick SJ, Donovan BT, Payne LA, Townsend C. Development of a high-throughput electrophysiological assay for the human ether-Ago-go related potassium channel hERG. J Pharmacol Toxicol Methods 2013; 67: 33-44.
39. Terstappen GC, Roncarati R, Dunlop J, Peri R. Screening technologies for ion channel drug discovery. Future Med Chem 2010; 2: 715-30.
40. Graef JD, Benson LC, Sidach SS, Wei H, Lippiello PM, Bencherif M, et al. Validation of a high-throughput, automated electrophysiology platform for the screening of nicotinic agonists and antagonists. J Biomol Screen 2013; 18: 116-27.
41. Xie X, Van Deusen AL, Vitko I, Babu DA, Davies LA, Huynh N, et al. Validation of high throughput screening assays against three subtypes of Ca(v)3 T-type channels using molecular and pharmacologic approaches. Assay Drug Dev Technol 2007; 5: 191-203.
42. Lee YT, Vasilyev DV, Shan QJ, Dunlop J, Mayer S, Bowlby MR. Novel pharmacological activity of loperamide and CP-339,818 on human HCN channels characterized with an automated electrophysiology assay. Eur J Pharmacol 2008; 581: 97-104.
43. Castle N, Printzenhoff D, Zellmer S, Antonio B, Wickenden A, Silvia C. Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms. Comb Chem High Throughput Screen 2009; 12: 107-22.
44. Ido K, Ohwada T, Yasutomi E, Yoshinaga T, Arai T, Kato M, et al. Screening quality for Ca2+-Activated potassium channel in IonWorks Quattro is greatly improved by using BAPTA-AM and ionomycin. J Pharmacol Toxicol Methods 2013 67: 16-24.
45. Du F, Yu H, Zou B, Babcock J, Long S, Li M. hERGCentral: a large database to store, retrieve, and analyze compound-human Ether-Ago-go related gene channel interactions to facilitate cardiotoxicity assessment in drug development. Assay Drug Dev Technol 2011; 9: 580-8.
46. Zhang H, Zou B, Yu H, Moretti A, Wang X, Yan W, et al. Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. Proc Natl Acad Sci U S A 2012; 109: 11866-71.
47. Beck EJ, Hutchinson TL, Qin N, Flores CM, Liu Y. Development and validation of a secondary screening assay for TRPM8 antagonists using QPatch HT. Assay Drug Dev Technol 2010; 8: 63-72.
48. Liu Y, Beck EJ, Flores CM. Validation of a patch clamp screening protocol that simultaneously measures compound activity in multiple states of the voltage-gated sodium channel Nav1.2. Assay Drug Dev Technol 2011; 9: 628-34.
49. Milligan CJ, Li J, Sukumar P, Majeed Y, Dallas ML, English A, et al. Robotic multiwell planar patch-clamp for native and primary mammalian cells. Nat Protoc 2009; 4: 244-55.
50. Hyrc KL, Bownik JM, Goldberg MP. Ionic selectivity of low-Affinity ratiometric calcium indicators: mag-Fura-2, Fura-2FF and BTC. Cell calcium 2000; 27: 75-86.
51. Titus SA, Beacham D, Shahane SA, Southall N, Xia M, Huang R, et al. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-A-go-go-related gene channel. Anal Biochem 2009; 394: 30-8.
52. Cheung YY, Yu H, Xu K, Zou B, Wu M, McManus OB, et al. Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl) butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor. J Med Chem 2012; 55: 6975-9.
53. Yu H, Wu M, Townsend SD, Zou B, Long S, Daniels JS, et al. Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Arylbicyclo[ 2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. ACS Chem Neurosci 2011; 2: 572-77.
54. Zou B, Yu H, Babcock JJ, Chanda P, Bader JS, McManus OB, et al. Pro filing diverse compounds by flux-And electrophysiology-based primary screens for inhibition of human Ether-A-go-go related gene potassium channels. Assay Drug Dev Technol 2010; 8: 743-54.
55. Mattmann ME, Yu H, Lin Z, Xu K, Huang X, Long S, et al. Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator. Bioorg Med Chem Lett 2012; 22: 5936-41.
56. Bridal TR, Margulis M, Wang X, Donio M, Sorota S. Comparison of human Ether-A-go-go related gene screening assays based on IonWorks Quattro and thallium flux. Assay Drug Dev Technol 2010; 8: 755-65.
57. Wang HR, Wu M, Yu H, Long S, Stevens A, Engers DW, et al. Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133. ACS Chem Biol 2011; 6: 845-56.
58. Raphemot R, Kadakia RJ, Olsen ML, Banerjee S, Days E, Smith SS, et al. Development and validation of fluorescence-based and automated patch clamp-based functional assays for the inward rectifier potassium channel Kir4.1. Assay Drug Dev Technol 2013; 11: 532-43.
59. Raphemot R, Weaver CD, Denton JS. High-throughput screening for small-molecule modulators of inward rectifier potassium channels. J Vis Exp 2013; 71: e4209.
60. Flaherty DP, Simpson DS, Miller M, Maki BE, Zou B, Shi J, et al. Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-Amide scaffold. Bioorg Med Chem Lett 2014; 24: 3968-73.
61. Bruner JK, Zou B, Zhang H, Zhang Y, Schmidt K, Li M. Identification of novel small molecule modulators of K2P18.1 two-pore potassium channel. Eur J Pharmacol 2014; 740: 603-10.
62. Zou B, Flaherty DP, Simpson DS, Maki BE, Miller MR, Shi J, et al. ML365: Development of bis-Amides as selective inhibitors of the KCNK3/TASK1 two pore potassium channel. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National Center for Biotechnology Information (US); 2010.
63. Jorgensen S, Dyhring T, Brown DT, Strobaek D, Christophersen P, Demnitz J. A high-throughput screening campaign for detection of Ca2+-Activated K+ channel activators and inhibitors using a fluorometric imaging plate reader-based Tl+-influx assay. Assay Drug Dev Technol 2013; 11: 163-72.
64. Jorgensen S, Johansen TH, Dyhring T. Fluorescence-based Tl+-influx assays as a novel approach for characterization of small-conductance Ca2+-Activated K+ channel modulators. Methods Mol Biol 2008; 491: 257-66.
65. Hanson GT, Hanson BJ. Fluorescent probes for cellular assays. Comb Chem High Throughput Screen 2008; 11: 505-13.
66. Horikawa K. Recent progress in the development of genetically encoded Ca2+ indicators. J Med Invest 2015; 62: 24-8.
67. Tsien RY. New calcium indicators and buffers with high selectivity against magnesium and protons: design, synthesis, and properties of prototype structures. Biochemistry 1980; 19: 2396-404.
68. Paredes RM, Etzler JC, Watts LT, Zheng W, Lechleiter JD. Chemical calcium indicators. Methods 2008; 46: 143-51.
69. Bailey S, Macardle PJ. A flow cytometric comparison of Indo-1 to fluo-3 and Fura Red excited with low power lasers for detecting Ca2+ flux. J Immunol Methods 2006; 311: 220-5.
70. Belardetti F, Tringham E, Eduljee C, Jiang X, Dong H, Hendricson A, et al. A fluorescence-based high-throughput screening assay for the identification of T-type calcium channel blockers. Assay Drug Dev Technol 2009; 7: 266-80.
71. Bandell M, Dubin AE, Petrus MJ, Orth A, Mathur J, Hwang SW, et al. High-throughput random mutagenesis screen reveals TRPM8 residues specifically required for activation by menthol. Nat Neurosci 2006; 9: 493-500.
72. Castillo B, Porzgen P, Penner R, Horgen FD, Fleig A. Development and optimization of a high-throughput bioassay for TRPM7 ion channel inhibitors. J Biomol Screen 2010; 15: 498-507.
73. Miller M, Wu M, Xu J, Weaver D, Li M, Zhu MX. High-Throughput Screening of TRPC Channel Ligands Using Cell-Based Assays. In: Zhu MX, editor. TRP Channels. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter1.
74. Zicha S, Radresa O, Laplante P, Morton M, Jones K, Main M, et al. Novel methodology to identify TRPV1 antagonists independent of capsaicin activation. J Biomol Screen 2013; 18: 544-55.
75. Luo J, Zhu Y, Zhu MX, Hu H. Cell-based calcium assay for medium to high throughput screening of TRP channel functions using FlexStation 3. J Vis Exp 2011; 54: e3149.
76. Bettini E, Sava A, Griffante C, Carignani C, Buson A, Capelli AM, et al. Identification and characterization of novel NMDA receptor antagonists selective for NR2A-over NR2B-containing receptors. J Pharmacol Exp Ther 2010; 335: 636-44.
77. Davies DJ, Crowe M, Lucas N, Quinn J, Miller DD, Pritchard S, et al. A novel series of benzimidazole NR2B-selective NMDA receptor antagonists. Bioorg Med Chem Lett 2012; 22: 2620-3.
78. Benjamin ER, Pruthi F, Olanrewaju S, Ilyin VI, Crumley G, Kutlina E, et al. State-dependent compound inhibition of Nav1.2 sodium channels using the FLIPR Vm dye: on-target and off-target effects of diverse pharmacological agents. J Biomol Screen 2006; 11: 29-39.
79. Diaz P, D'Suze G, Salazar V, Sevcik C, Shannon JD, Sherman NE, et al. Antibacterial activity of six novel peptides from Tityus discrepans scorpion venom. A fluorescent probe study of microbial membrane Na+ permeability changes. Toxicon 2009; 54: 802-17.
80. Roder P, Hille C. ANG-2 for quantitative Na+ determination in living cells by time-resolved fluorescence microscopy. Photochem Photobiol Sci 2014; 13: 1699-710.
81. Du Y, Days E, Romaine I, Abney KK, Kaufmann K, Sulikowski G, et al. Development and Validation of a Thallium Flux-Based Functional Assay for the Sodium Channel NaV1.7 and Its Utility for Lead Discovery and Compound Profiling. ACS Chem Neurosci 2015; 6: 871-8.
82. Zhang H, Zou B, Du F, Xu K, Li M. Reporting sodium channel activity using calcium flux: pharmacological promiscuity of cardiac Nav1.5. Mol Pharmacol 2015; 87: 207-17.
83. Sui J, Cotard S, Andersen J, Zhu P, Staunton J, Lee M, et al. Optimization of a Yellow fluorescent protein-based iodide influx high-throughput screening assay for cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Assay Drug Dev Technol 2010; 8: 656-68.
84. Galietta LJ, Springsteel MF, Eda M, Niedzinski EJ, By K, Haddadin MJ, et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001; 276: 19723-8.
85. Namkung W, Phuan PW, Verkman AS. TMEM16A inhibitors reveal TMEM16A as a minor component of calcium-Activated chloride channel conductance in airway and intestinal epithelial cells. J Biol Chem 2011; 286: 2365-74.
86. Namkung W, Thiagarajah JR, Phuan PW, Verkman AS. Inhibition of Ca2+-Activated Cl-channels by gallotannins as a possible molecular basis for health benefits of red wine and green tea. Faseb J 2010; 24: 4178-86.
87. Namkung W, Yao Z, Finkbeiner WE, Verkman AS. Small-molecule activators of TMEM16A, a calcium-Activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. Faseb J 2011; 25: 4048-62.
88. Peters CJ, Yu H, Tien J, Jan YN, Li M, Jan LY. Four basic residues critical for the ion selectivity and pore blocker sensitivity of TMEM16A calcium-Activated chloride channels. Proc Natl Acad Sci U S A 2015; 112: 3547-52.
89. Kruger W, Gilbert D, Hawthorne R, Hryciw DH, Frings S, Poronnik P, et al. A yellow fluorescent protein-based assay for high-throughput screening of glycine and GABAA receptor chloride channels. Neurosci Lett 2005; 380: 340-5.
90. Johansson T, Norris T, Peilot-Sjogren H. Yellow Fluorescent Protein-Based Assay to Measure GABAA Channel Activation and Allosteric Modulation in CHO-K1 Cells. PloS One 2013; 8: e59429.
91. Johansson T, Norris T, Peilot-Sjogren H. Yellow fluorescent proteinbased assay to measure GABA(A) channel activation and allosteric modulation in CHO-K1 cells. PloS One 2013; 8: e59429.
92. Lieu PT, Machleidt T, Thyagarajan B, Fontes A, Frey E, Fuerstenau-Sharp M, et al. Generation of site-specific retargeting platform cell lines for drug discovery using phiC31 and R4 integrases. J Biomol Screen 2009; 14: 1207-15.